AIDS
Conditions
Interventions
Experimental group:HAART + Semaglutide Tablets
Control Group B:HAART + lenalidomide tablets
Control Group A:HAART + Mecobalamin Tablets
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Hospitalized patients aged 18–65 years; 2.Confirmed HIV infection and receiving HAART >= 6 months, with plasma viral load 5/mL, protein > 45 mg/dL, elevated cytokines such as CSF IL-6, or intracranial lesions shown on cranial MRI); 4.Voluntarily signed the informed consent form, and able to comply with regular follow-up, specimen collection, and monitoring of adverse reactions related to treatment; 5.Agree to use effective contraception from 4 weeks before the start of the study to 4 weeks after the end of the study;
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women, or individuals planning to become pregnant during the study period; 2.Patients with poor treatment compliance. 3.Received immunosuppressive agents, other immunomodulators, or cytotoxic drugs within 6 months prior to screening. 4.Patients with a history or family history of medullary thyroid carcinoma; diabetic ketoacidosis; a history of or high risk for pancreatitis; severe gastrointestinal diseases; severe underlying cardiovascular, cerebrovascular, hepatic, or renal diseases; myelosuppression with neutrophils < 1000/mm^3 or platelets < 75 000/mm^3; venous or arterial thromboembolism; hypersensitivity to the study drug; or other contraindications to study treatment. 5.Unwilling to sign the informed consent form; 6.Positive etiological test for intracranial infection (e.g., bacteria, fungi, Mycobacterium tuberculosis, etc.). 7.Complicated with other central nervous system diseases (e.g., brain tumor, multiple sclerosis, acute cerebrovascular disease). 8.Use of immunosuppressive agents (e.g., glucocorticoids), other immunomodulators (e.g., interferon, thymosin), or cytotoxic drugs within 6 months prior to screening; 9.Planned use of anti-inflammatory agents other than antifungals and antivirals (e.g., nonsteroidal anti-inflammatory drugs) during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of intracranial inflammation control in patients with HIV complicated with refractory intracranial inflammation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction and disappearance of HIV reservoir, and improvement of microecology; | — |
Countries
China
Contacts
Public ContactZhu Biao
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed